Back
Top 0.6%
14.6%
#1
14.6%
Top 0.4%
14.6%
Top 16%
6.4%
Top 0.6%
6.4%
Top 46%
6.0%
Top 79%
5.6%
Top 2%
3.9%
Top 0.2%
3.6%
Top 12%
1.9%
Top 3%
1.3%
Top 3%
1.2%
Top 1%
1.0%
Top 5%
1.0%
Top 1%
0.9%
Top 6%
0.9%
Top 13%
0.7%
Top 7%
0.7%
Top 23%
0.7%
Pharmacological weight loss with incretin-based therapies does not result in a disproportionate loss of muscle mass or function in obese mice and humans.
2025-07-28
endocrinology
Title + abstract only
View on medRxiv
Show abstract
The new generation of incretin-based therapies are potent anti-obesity medications (AOMs) that offer the first non-surgical treatment for 936 million patients globally suffering from being overweight or obese[1]. However, clinical data suggest that incretin-mimetics could cause a disproportionate decrease in lean body mass (LBM) [2, 3], raising a concern for deterioration of skeletal muscle and acceleration of sarcopenic obesity[4]. Unfortunately, muscle mass and function are not routinely asses...
Predicted journal destinations
1
The Journal of Clinical Endocrinology & Metabolism
26 training papers
2
Frontiers in Endocrinology
20 training papers
3
eLife
262 training papers
4
Nature Communications
483 training papers
5
Diabetologia
23 training papers
6
Scientific Reports
701 training papers
7
PLOS ONE
1737 training papers
8
JCI Insight
63 training papers
9
International Journal of Obesity
17 training papers
10
BMC Medicine
155 training papers
11
Nutrients
43 training papers
12
Communications Medicine
63 training papers
13
Cell Reports
25 training papers
14
Cell Reports Medicine
49 training papers
15
The Journals of Gerontology: Series A
19 training papers
16
Cell Genomics
34 training papers
17
iScience
74 training papers
18
Human Molecular Genetics
28 training papers
19
Journal of Clinical Medicine
77 training papers